Annals of Hematology

, Volume 92, Issue 10, pp 1345–1350 | Cite as

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib

  • Paul La Rosée
  • Philippe Martiat
  • Armin Leitner
  • Thomas Klag
  • Martin C. Müller
  • Philipp Erben
  • Thomas Schenk
  • Susanne Saussele
  • Andreas Hochhaus
Original Article

Abstract

Intermittent dosing of dasatinib with a once daily regimen has been shown to reduce side effects while preserving clinical efficacy in early and advanced phase chronic myeloid leukemia (CML). Yet, hematologic toxicity and fluid retention demand a dose modification or treatment discontinuation in selected patients. Patients resistant or intolerant to imatinib were retrospectively evaluated based on the toxicity-guided administration of a dose-reduced dasatinib regimen. Patients were treated with an on/off regimen (3 to 5 days on, 2 to 4 days off) to allow regression of dasatinib-dependent off-target toxicity. Patients were followed up by routine hematologic and cytogenetic assessment and molecular monitoring to safeguard clinical response to the altered drug schedule. Thirty-three CML patients primarily in chronic phase with imatinib intolerance (n = 11) or resistance (n = 22) were investigated. Nonexclusive reasons for dose reduction were hematologic toxicity (17/33, 51 %) and pleural effusions (18/33, 55 %). On/off treatment with a weekend drug holiday significantly reduced pleural effusions and hematologic toxicity. Eighteen of 31 (58 %) patients showed effective disease control despite reduced total weekly dasatinib doses, either demonstrated by achieving an improved response level (12/31) or keeping the response level achieved by conventional continuous dosing (6/31). Of note, 10/12 patients with subsequently improved response have been treated for a minimum of 6 months with continuous dosing dasatinib regimens without having achieved the response level achieved after allowing drug holiday. Weekend treatment interruption of dasatinib allows continuation of dasatinib treatment for patients suffering from side effects. These data mandate prospective investigation of alternative intermittent targeting regimens.

Keywords

Dasatinib Resistance CML Tolerability Toxicity Dosing 

Supplementary material

277_2013_1769_MOESM1_ESM.pdf (331 kb)
Fig. 1(PDF 330 kb)

References

  1. 1.
    Sprycel (dasatinib) package insert (2010). Princeton, New Jersey, Bristo-Myers Squibb CompanyGoogle Scholar
  2. 2.
    Kantarjian HM, Shah NP, Cortes JE et al (2012) Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119(5):1123–1129PubMedCrossRefGoogle Scholar
  3. 3.
    Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531–2541PubMedCrossRefGoogle Scholar
  4. 4.
    Fabian MA, Biggs WH 3rd, Treiber DK et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23(3):329–336PubMedCrossRefGoogle Scholar
  5. 5.
    O’Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65(11):4500–4505PubMedCrossRefGoogle Scholar
  6. 6.
    van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35(8):692–706PubMedCrossRefGoogle Scholar
  7. 7.
    Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105(1):3–7PubMedCrossRefGoogle Scholar
  8. 8.
    Shah NP, Kantarjian HM, Kim DW et al (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26(19):3204–3212PubMedCrossRefGoogle Scholar
  9. 9.
    Kantarjian H, Cortes J, Kim DW et al (2009) Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113(25):6322–6329PubMedCrossRefGoogle Scholar
  10. 10.
    Jabbour E, Deininger M, Hochhaus A (2011) Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25(2):201–210PubMedCrossRefGoogle Scholar
  11. 11.
    Hochhaus A, Muller MC, Radich J et al (2009) Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 23(9):1628–1633PubMedCrossRefGoogle Scholar
  12. 12.
    Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24):2260–2270PubMedCrossRefGoogle Scholar
  13. 13.
    Shah NP, Kasap C, Weier C et al (2008) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14(6):485–493PubMedCrossRefGoogle Scholar
  14. 14.
    Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041–6051PubMedCrossRefGoogle Scholar
  15. 15.
    Branford S, Fletcher L, Cross NC et al (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112(8):3330–3338PubMedCrossRefGoogle Scholar
  16. 16.
    Cross NC, White H, Muller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172–2175PubMedCrossRefGoogle Scholar
  17. 17.
    Emig M, Saussele S, Wittor H et al (1999) Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13(11):1825–1832PubMedCrossRefGoogle Scholar
  18. 18.
    Cross NC, Hughes TP, Feng L et al (1993) Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 84(1):67–74PubMedCrossRefGoogle Scholar
  19. 19.
    Soverini S, Martinelli G, Amabile M et al (2004) Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin Chem 50(7):1205–1213PubMedCrossRefGoogle Scholar
  20. 20.
    Ernst T, Erben P, Muller MC et al (2008) Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 93(2):186–192PubMedCrossRefGoogle Scholar
  21. 21.
    Snead JL, O’Hare T, Adrian LT et al (2009) Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 114(16):3459–3463PubMedCrossRefGoogle Scholar
  22. 22.
    le Coutre P, Mologni L, Cleris L et al (1999) In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91(2):163–168PubMedCrossRefGoogle Scholar
  23. 23.
    Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399–401PubMedCrossRefGoogle Scholar
  24. 24.
    Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879–894PubMedCrossRefGoogle Scholar
  25. 25.
    Brave M, Goodman V, Kaminskas E et al (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14(2):352–359PubMedCrossRefGoogle Scholar
  26. 26.
    Rohrbacher M, Berger U, Hochhaus A et al (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23(3):602–604PubMedCrossRefGoogle Scholar
  27. 27.
    Hochhaus A, Kantarjian HM, Baccarani M et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6):2303–2309PubMedCrossRefGoogle Scholar
  28. 28.
    Ibrahim AR, Eliasson L, Apperley JF et al (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14):3733–3736PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Paul La Rosée
    • 1
    • 4
  • Philippe Martiat
    • 2
  • Armin Leitner
    • 3
  • Thomas Klag
    • 1
  • Martin C. Müller
    • 3
  • Philipp Erben
    • 3
  • Thomas Schenk
    • 1
  • Susanne Saussele
    • 3
  • Andreas Hochhaus
    • 1
  1. 1.Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin IIUniversitätsklinikum JenaJenaGermany
  2. 2.Institut BordetUniversity of BrusselsBrusselsBelgium
  3. 3.III. Medizinische Universitätsklinik, Medizinische Fakultät MannheimUniversität HeidelbergMannheimGermany
  4. 4.Klinik für Innere Medizin II, Hämatologie/OnkologieUniversitätsklinikum JenaJenaGermany

Personalised recommendations